Table 1 The ways MSCs on the innate immune responses during LI.
From: Mesenchymal stem cells for lung diseases: focus on immunomodulatory action
Lung Diseases | Animal Model | Intervention (MSCs/EVs) | Regulation of Immune Cell | Outcomes | Mechanism | References |
|---|---|---|---|---|---|---|
ALI | Injected intratracheal with PA in C57BL/6 mice | AMSCs | Increased the phagocytic ability of macrophages; Reduced white blood cell count | Reduced the bacterial load, inflammation of lung tissue and histopathological damage | Reduced the activation of NLRC4 inflammasome | [97] |
ALI | Injected intraperitoneally with LPS in C57BL/6 mice | AMSC-CM activated by flagellin | Induced macrophage polarization to M2 profile | Alleviated the lung exudation; Inhibited inflammatory cell recruitment in lung tissue; Decreased the concentration of inflammatory factors | / | [98] |
ALI | Injected intraperitoneally with LPS in BALB/c mice | BMSCs | Induced further macrophage polarization to M2 profile; Decreased absolute numbers of neutrophils | Inibited Inflammatory and oxidative stress reaction | Activated STC2/Nrf2 pathway | [31] |
ALI | Injected intraperitoneally with CEES in C57BL/6 mice | AMSCs | Prevented the differentiation of CEES-stimulated macrophages into M1 phenotype and stimulated the polarization to M2 phenotype | Reduced progressive histopathologic changes in the lung; Reduced inflammatory cytokines | / | [99] |
ALI | Injected intraperitoneally with LPS in Sprague-Dawley rats | pMSCs | Reduced the expression of TNF-α and increased IL-10 in RAW264.7 macrophage inflammation model; Reduced white blood cell count | Alleviated the infiltration of inflammatory cells, pulmonary hyperemia and hemorrhage, and interstitial edema | Downregulated CXCL12 | [100] |
ALI | Injected intraperitoneally with LPS in Sprague-Dawley rats | BMSC-Exos | Prevented LPS-induced alveolar macrophage apoptosis and autophagy stress | Improved pathological changes in lung tissue; Improved pulmonary vascular permeability; Regulated the inflammatory cytokines | Regulated miR-384-5p/Beclin-1 pathway | [101] |
ALI | Injected intraperitoneally with LPS in C57BL/6 mice | HS-pretreatedhUCMSCs | Enhanced immunoregulatory effect in inducing M2 macrophage polarization; Decreased absolute numbers of neutrophils | Improved the pathological changes and lung damage-related indexes; Reduced the proinflammatory cytokine levels | Inhibited NLRP3 inflammasome activation | [102] |
ALI | / | BMSCs | Down-regulated the elevated levels of autophagy in macrophages | / | Activated PI3K/Akt/ HO-1 signaling pathway | [39] |
ALI | Injected intraperitoneally with LPS in C57BL/6 mice | MSC-Exos | Inhibited LPS-induced glycolysis in macrophages and production of proinflammatory cytokines | Alleviated sepsis-induced ALI and systemic inflammation; Improved survival rate | / | [103] |
ALI | Severe burn Sprague-Dawley rats | hUCMSC-Exos | Modulated macrophage M2 polarization | Reduced inflammation and oxidative stress | Regulated miR-451 /MIF/PI3K/AKT signaling pathway | [43] |
ALI | Injected intraperitoneally with LPS in C57BL/6 mice | hUCMSCs | Increased PD-L1 expression in the lung macrophages | Decreased total protein exudation concentration and cell number in BALF; Reduced pathological damage and inflammation | Regulated COX2/PGE2 signaling pathway | [36] |
ALI | Injected with LPS in C57BL/6 mice | BMSCs | Suppressed the activation of alveolar macrophages | Decreased total protein exudation concentration; Alleviated alveolar epithelial damage; Reduced inflammation | Regulated PGE2/EP4R signaling pathway | [104] |
ALI | Ligated and punctured cecum in C57BL/6 mice | AMSC-Exos | Inhibited the LPS-mediated release of IL-27 in macrophages; Reduced the number of pulmonary macrophages | Decreased pulmonary edema and pulmonary vascular leakage; Reduced inflammation | / | [105] |
ALI | Injected with LPS in C57BL/6 mice | AMSC-Exos | Rendered macrophages shifting from M1 proinflammatory to M2-polarized anti-inflammatory phenotype | Alleviated lung inflammation and injury | Transferred mitochondrial component | [46] |
ALI | Injected with LPS in C57BL/6 mice | Nrf2 -hAMSC-EVs | Promoted M2-like polarization; Inhibited infiltration of neutrophils | Reduced apoptosis and inflammation | Inhibited the activation of the NLRP3 inflammasome | [106] |
ALI | Injected with LPS in C57BL/6 mice | Hypoxia-preconditioned MSC-CM | Promoted anti-inflammatory polarization; Restored efferocytosis of macrophages | Promoted resolution of inflammation | / | [107] |
ALI | Injected with LPS in C57BL/6 mice | MSC-EVs | Promoted M2-like polarization | Reduced the expression of pro-inflammatory cytokines, increased the expression of anti-inflammatory cytokines; Decreased pathological scores | / | [108] |
ALI | Ligated and punctured cecum in mice | AMSC-Exos | Promoted M2 polarization and TGF -β secretion | Inhibited inflammatory responses | / | [109] |
ALI | Injected with LPS in C57BL/6 mice | PEG2-MSCs | Promoted M2 polarization; Decreased absolute numbers of neutrophils | Reduced cellular infiltration; Reduced histopathological changes and pro-inflammatory cytokines and increased anti-inflammatory cytokines | / | [32] |
ALI | Injected with LPS in C57BL/6 mice | UCMSC-ABs | Inhibited pro‐inflammatory polarization and cytokines production of macrophages; Decreased absolute numbers of neutrophils | Suppressed lung inflammation | Regulated PDL1–PD1 pathway; Reprogrammed metabolic pathways | [110] |
ALI | Injected with E.coil in ICR mice | UCMSCs | Regulated on M1/M2 macrophage polarization; Decreased absolute numbers of neutrophils | Attenuated lung injury and inflammation | Secreted SOCS3 | [111] |
ALI | Cardiopulmonary bypass related lung injury in Sprague-Dawley rats | BMSC-Exos | Suppressed ROS production and down-regulated the levels of inflammatory cytokines of macrophages | Attenuated histological changes; Down-regulated inflammatory cytokine levels; Alleviated oxidative stress | Regulated NF-κB p65 and Akt/Nrf2/HO-1 signaling pathways | [112] |
ALI | / | LPS-BMSC-Exos | Suppressed pro-inflammatory polarization and promoted anti-inflammatory polarization of alveolar macrophages | Suppressed lung inflammation | Regulated miR- 150-3p/ INHBA signaling pathway | [44] |
ARDS | Injected intraperitoneally with LPS in C57BL/6 mice | BMSC-Exos | Ameliorated LPS-induced alveolar macrophage M1 polarization | Exerted anti-inflammatory effects | Inhibited glycolysis via inhibition of HIF-1α | [113] |
ARDS | Injected with LPS in BALB/c mice | hUCMSCs | Promoted M2-like polarization; Decreased absolute numbers of neutrophils | Improved lung injury; Attenuated inflammatory cell infiltration | / | [114] |
ARDS | Injected with Klebsiella pneumoniae in C57BL/6 mice | PMSCs | Preserved resident alveolar macrophage over bone marrow–recruited macrophage and drived the overall milieu to an M2 immunomodulatory phenotype; Enhanced multiple antibacterial functions in alveolar macrophage | Decreased pulmonary inflammation and tissue injury | Secreted IL-1β | [115] |
ARDS | / | hUCMSCs | Increased IL-10 expression in alveolar macrophages; Induced alveolar macrophage polarization | / | Regulated STC1/ PI3K/AKT/mTOR pathway | [37] |
Asthma | Injected intraperitoneally with OVA in BALB/c mice | hUCMSCs | Reduced M2 macrophages; Decreased absolute numbers of eosinophils | Reducted airway hyperresponsiveness and inflammation | / | [52] |
Asthma | Instillated intranasally with total house dust mite extracts in C57BL/6 mice | Serum from asthmatic mice-stimulated BMSCs | Induced further macrophage polarization to M2 profile; Decreased absolute numbers of neutrophils and eosinophils | Reducted lung inflammation and remodeling; Improved lung mechanics | / | [53] |
Asthma | Injected intraperitoneally with OVA/CFA in BALB/c mice | hUCMSC-Exos | Regulated macrophage polarization; Decreased absolute numbers of neutrophils | Reduced inflammation | Regulated NF-κB and PI3K/AKT signaling dependent on TRAF1 | [116] |
Asthma | Injected intraperitoneally with OVA in BALB/c mice | MSC-EVs | Inhibited the recruitment and polarization of lung macrophages; Decreased absolute numbers of eosinophils | Ameliorated allergic airway inflammation | / | [54] |
Asthma | Injected intraperitoneally with OVA in C57BL/6 mice | MSC-Exos | Enhanced lung interstitial macrophages ratios and high level of IL-10; Decreased absolute numbers of eosinophils | Decrease inflammation index, histological mucus index, total cells and cytokines | / | [55] |
Asthma | IL-13 transgenic mice | Liproxstatin-1-primed hUCMSCs/ hUCMSCs | Alterated lung macrophage populations; Decreased absolute numbers of neutrophils and eosinophils | Reduced airway inflammation and fibrosis | / | |
Asthma | Injected intraperitoneally with IL-33 in C57BL/6 mice | iPSC-MSC-EV | Mitigated the activation of ILC2s | Ameliorated ILC2-dominant allergic airway inflammation | Delivered miR-146a-5p | [56] |
Asthma | Instillated intranasally with total house dust mite extracts in BALB/c mice | BMSCs | Decreased absolute numbers of neutrophils, eosinophils and lymphocytes; Induced lung macrophage polarization into suppressive phenotype | Inhibited airway hyper-responsiveness and bronchoconstriction; Decreased airway inflammation | / | [119] |
Asthma | Instillated intranasally with total house dust mite extracts in C57BL/6 mice | Eicosapentaenoic acid -stimulated BMSCs | Induced macrophage polarization to the M2; Decreased absolute numbers of neutrophils and eosinophils | Reduced lung morphological changes, remodeling, and mucus hypersecretion; Improved lung mechanics | / | [120] |
IPF | Injected intratracheal with bleomycin in C57BL/6 mice | hUCMSCs | Reduced M2c subset of M2 monocyte-derived macrophages; Decreased absolute numbers of neutrophils and eosinophils | Attenuated inflammation and the degree of lung fibrosis | / | [121] |
IPF | Injected intratracheal with bleomycin in C57BL/6 mice | hAMSCs | Increased macrophage polarization toward M2, and reduced the antigen-presentation potential of macrophages and dendritic cells | Decreased alveolar obliteration; Decreased extracellular matrix proteins and α‐SMA | / | [21] |
BPD | Hyperoxia-induced in FVB mice/ Sprague-Dawley rats | MSC-Exos | Regulated macrophage phenotype | Restored lung architecture; Improved pulmonary development and ameliorates septal fibrosis; Rescued loss of peripheral pulmonary blood vessels and peripheral pulmonary arterial remodeling; Modulated inflammation | / | |
BPD | Hyperoxia-induced in pregnant Sprague-Dawley rats | hUCMSCs | Regulated Macrophage Polarization | Attenuated inflammation | Regulated PTX3/TSG14 pathway | [124] |
BPD | Hyperoxia-induced in mice | hUCMSCs | Decreased FPR2 levels in alveolar macrophages | Reduced levels of inflammatory cytokines (IL-1α and TNF-α) | / | [125] |
Silicosis | Instilled intratracheally silica suspension in C57BL/6 mice | BMSCs | Decreased the macrophage infiltration | Attenuated inflammation | Regulated the activation of inflammasome by secreting TSG-6 | [126] |
PAH | Injected with the VEGF receptor 2 antagonist in Sprague-Dawley rats | MSC-EVs | Induced further macrophage polarization to M2 profile | Reduced right ventricular hypertrophy and muscularization of peripheral pulmonary vessel | / | [127] |
DAH | Injected intraperitoneally with sterile filtrated pristine in C57BL/6 J mice | hUCMSC-Exos | Enhanced M2 polarization | Alleviated pathological symptoms; Attenuated the alveolar injuries and inflammatory responses | / | [128] |
RILI | Radiated with 20 Gy 60Co γ-ray in Sprague-Dawley rats | miR-21-knockout BMSCs | Controlled macrophage polarization | Decreased RILI-induced acute inflammation; Reduced mortality in rats with RILI | / | [129] |